Crescent Biopharma (CBIO) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Oct 27, 2026

Net selling: insiders sold $286K and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: -$286K netNet selling
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Jun 30, 2026: 1 added, 0 cutMore adding
Federal contractsUSAspending.gov, last 12 months: No awardsNone on record

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about CBIO filings

Are insiders buying or selling Crescent Biopharma, Inc. (CBIO) stock?

Net selling: insiders sold $286K and bought $0 of CBIO stock on the open market in the 90 days to Oct 27, 2026, according to SEC Form 4 filings. $286K of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Brumm, Joshua T (Chief Executive Officer), who sold $160K. The latest filing was on Sep 18, 2026.

Which members of Congress have traded CBIO recently?

None. No member of Congress disclosed a CBIO trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this CBIO smart-money data?

This summary uses filings available on Oct 27, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on CBIO

Lean long1 source:
- Funds
Lean short1 source:
- Insiders

Top traders
No tracked positions at the last update
Insiders
Lean short3 sales · $249K
3 of 3 on scheduled plans. Form 4 filings.
Politicians
No recent politician filings found
Funds
- Balyasny, added +$26.4M, holdings at Mar 31
- BlackRock, added +$20.8M, holdings at Jun 30
Lean long · thin2 added · 0 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about CBIO filings

Are insiders buying or selling Crescent Biopharma, Inc. (CBIO) stock?

Which members of Congress have traded CBIO recently?

None. No member of Congress disclosed a CBIO trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this CBIO smart-money data?

Funds

What funds are doing

2 moves · 6 mo

Buys/Adds$47.2M

Buys/Adds (2)

BA
Balyasny
Dmitry Balyasny · Q1 2026 13F
$26.4M
added
Signals like this: n=13770, 53% finished lower at D15, median -0.4% vs SPY -0.4%
BR
BlackRock
Q2 2026 13F
$20.8M
added

Unlock everything for $29/month

Unlock for $29/month

Reported Jul 30, 2026

Earnings came in 2.8% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Jul 30, 2026

Period ending

Jun 30, 2026

Earnings per share

-$0.62+2.83% beat

-$0.64 expected

Revenue

$0.00

SEC filing

EPS: Yahoo Finance

Next report

Estimated report: Nov 5, 2026, in 9 days

Previous reports

Period ending	Reported	EPS / estimate	EPS surprise	Revenue / income	Surprise
Jun 30, 2026	Jul 30, 2026	-$0.62 / -$0.64Yahoo Finance	+2.83% beat	$0.00 No estimateSEC filing	Unavailable
Mar 31, 2026	Apr 29, 2026	-$0.70 / -$0.79Yahoo Finance	+11.02% beat	$1.0M No estimateSEC filing	Unavailable
Dec 31, 2025	Feb 26, 2026	-$4.92 / -$2.82Yahoo Finance	-74.47% miss	$0.00 No estimate	Unavailable
Sep 30, 2025	Nov 6, 2025	-$1.37 / -$1.39Yahoo Finance	+1.26% beat	$0.00 No estimate	Unavailable
Jun 30, 2025	Jul 31, 2025	-$3.72 / -$3.68Alpha Vantage	-1.09% miss	$0.00 No estimateSEC filing	Unavailable
Mar 31, 2025	May 14, 2025	-$18.39 / -$3.64Alpha Vantage	-$14.75 miss	$0.00 No estimateSEC filing	Unavailable
Dec 31, 2024	Feb 13, 2025	-$0.08 / -$0.09Alpha Vantage	+$0.01 beat	$0.00 No estimateSEC filing	Unavailable
Sep 30, 2024	Nov 13, 2024	-$15.24 / -$0.11Alpha Vantage	-$15.13 miss	Unavailable	Unavailable

EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.

Open: $13.36
52-wk high: $27.41
High: $13.36
52-wk low: $8.72
Low: $12.62
Prev close: $13.14
Mkt cap: $476.2M
ROE: -160.7%
P/S: 40.1x
P/B: 3.3x
Profit margin: +0.0%
Op margin: -1433.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $476M

Valuation

P/S40.08
P/B3.31

Quality

Operating margin-1433.0%
ROE-160.7%
ROA-69.2%

Growth

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

0 / 100

RSI 14

42balanced

20D volatility

65%annualized

52-week range

$12.82

$8.72$27.41

20D support

$11.78recent floor

20D resistance

$15.62recent ceiling

Returns

5D +8.3%20D -8.4%60D -14.6%

Price vs moving averages

SMA20 -5.5%SMA50 -19.8%SMA200 -19.0%

Volume pace

0.62xvs prior 20D

Smart money at a glance

Filings to Oct 27, 2026

Net selling: insiders sold $286K and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: -$286K netNet selling
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Jun 30, 2026: 1 added, 0 cutMore adding
Federal contractsUSAspending.gov, last 12 months: No awardsNone on record

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about CBIO filings

Are insiders buying or selling Crescent Biopharma, Inc. (CBIO) stock?

Which members of Congress have traded CBIO recently?

None. No member of Congress disclosed a CBIO trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this CBIO smart-money data?

13F: filed up to 45 days late.

Smart money on CBIO

Lean long1 source:
- Funds
Lean short1 source:
- Insiders

Top traders
No tracked positions at the last update
Insiders
Lean short3 sales · $249K
3 of 3 on scheduled plans. Form 4 filings.
Politicians
No recent politician filings found
Funds
- Balyasny, added +$26.4M, holdings at Mar 31
- BlackRock, added +$20.8M, holdings at Jun 30
Lean long · thin2 added · 0 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about CBIO filings

Are insiders buying or selling Crescent Biopharma, Inc. (CBIO) stock?

Which members of Congress have traded CBIO recently?

None. No member of Congress disclosed a CBIO trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this CBIO smart-money data?

Funds

What funds are doing

2 moves · 6 mo

Buys/Adds$47.2M

Buys/Adds (2)

BA
Balyasny
Dmitry Balyasny · Q1 2026 13F
$26.4M
added
Signals like this: n=13770, 53% finished lower at D15, median -0.4% vs SPY -0.4%
BR
BlackRock
Q2 2026 13F
$20.8M
added

Unlock everything for $29/month

Unlock for $29/month

Reported Jul 30, 2026

Earnings came in 2.8% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Jul 30, 2026

Period ending

Jun 30, 2026

Earnings per share

-$0.62+2.83% beat

-$0.64 expected

Revenue

$0.00

SEC filing

EPS: Yahoo Finance

Next report

Estimated report: Nov 5, 2026, in 9 days

Previous reports

Period ending	Reported	EPS / estimate	EPS surprise	Revenue / income	Surprise
Jun 30, 2026	Jul 30, 2026	-$0.62 / -$0.64Yahoo Finance	+2.83% beat	$0.00 No estimateSEC filing	Unavailable
Mar 31, 2026	Apr 29, 2026	-$0.70 / -$0.79Yahoo Finance	+11.02% beat	$1.0M No estimateSEC filing	Unavailable
Dec 31, 2025	Feb 26, 2026	-$4.92 / -$2.82Yahoo Finance	-74.47% miss	$0.00 No estimate	Unavailable
Sep 30, 2025	Nov 6, 2025	-$1.37 / -$1.39Yahoo Finance	+1.26% beat	$0.00 No estimate	Unavailable
Jun 30, 2025	Jul 31, 2025	-$3.72 / -$3.68Alpha Vantage	-1.09% miss	$0.00 No estimateSEC filing	Unavailable
Mar 31, 2025	May 14, 2025	-$18.39 / -$3.64Alpha Vantage	-$14.75 miss	$0.00 No estimateSEC filing	Unavailable
Dec 31, 2024	Feb 13, 2025	-$0.08 / -$0.09Alpha Vantage	+$0.01 beat	$0.00 No estimateSEC filing	Unavailable
Sep 30, 2024	Nov 13, 2024	-$15.24 / -$0.11Alpha Vantage	-$15.13 miss	Unavailable	Unavailable

Open: $13.36
52-wk high: $27.41
High: $13.36
52-wk low: $8.72
Low: $12.62
Prev close: $13.14
Mkt cap: $476.2M
ROE: -160.7%
P/S: 40.1x
P/B: 3.3x
Profit margin: +0.0%
Op margin: -1433.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $476M

Valuation

P/S40.08
P/B3.31

Quality

Operating margin-1433.0%
ROE-160.7%
ROA-69.2%

Growth

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

0 / 100

RSI 14

42balanced

20D volatility

65%annualized

52-week range

$12.82

$8.72$27.41

20D support

$11.78recent floor

20D resistance

$15.62recent ceiling

Returns

5D +8.3%20D -8.4%60D -14.6%

Price vs moving averages

SMA20 -5.5%SMA50 -19.8%SMA200 -19.0%

Volume pace

0.62xvs prior 20D

Crescent Biopharma, Inc.

Smart money at a glance

What do analysts expect?

Questions about CBIO filings

Smart money on CBIO

Questions about CBIO filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 2.8% above what analysts expected.

Estimated report: Nov 5, 2026, in 9 days

Previous reports

Is the business strong?

Price structure

Crescent Biopharma, Inc.

Smart money at a glance

What do analysts expect?

Questions about CBIO filings

Smart money on CBIO

Questions about CBIO filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 2.8% above what analysts expected.

Estimated report: Nov 5, 2026, in 9 days

Previous reports

Is the business strong?

Price structure

Crescent Biopharma, Inc.

Overview

Questions about CBIO filings

Smart money

Unlock everything for $29/month

Earnings

Financials

Technicals

Crescent Biopharma, Inc.

Overview

Questions about CBIO filings

Smart money

Unlock everything for $29/month

Earnings

Financials

Technicals